Clinical Trials Directory

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : filgrastim
  • drug : tacrolimus
  • drug : dasatinib
  • drug : dexamethasone
  • drug : doxorubicin hydrochloride
  • drug : etoposide
  • drug : leucovorin calcium
  • drug : methotrexate
  • drug : methylprednisolone
  • drug : prednisone
  • drug : vincristine sulfate
  • drug : cyclophosphamide
  • drug : cytarabine
  • drug : sirolimus
  • other : laboratory biomarker analysis
  • procedure : allogeneic hematopoietic stem cell transplantation
  • procedure : peripheral blood stem cell transplantation
  • radiation : total-body irradiation

Phase: Phase 2


Ages Eligible For Study:

18 Years - 60 Years

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting

Footer Links: